<table>
<thead>
<tr>
<th>Category</th>
<th>Subgroup</th>
<th>CT + BEV better</th>
<th>CT better</th>
<th>HR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>All ($N = 2591$)</td>
<td></td>
<td></td>
<td>0.94</td>
<td>0.75–1.18</td>
</tr>
<tr>
<td>Age, years</td>
<td>&lt;40 ($N = 484$)</td>
<td></td>
<td></td>
<td>0.88</td>
<td>0.51–1.54</td>
</tr>
<tr>
<td></td>
<td>40–&lt;65 ($N = 1868$)</td>
<td></td>
<td></td>
<td>0.89</td>
<td>0.68–1.17</td>
</tr>
<tr>
<td></td>
<td>≥65 ($N = 239$)</td>
<td></td>
<td></td>
<td>1.50</td>
<td>0.73–3.05</td>
</tr>
<tr>
<td>Baseline ECOG PS</td>
<td>0 ($N = 2388$)</td>
<td></td>
<td></td>
<td>0.98</td>
<td>0.77–1.25</td>
</tr>
<tr>
<td></td>
<td>1 ($N = 192$)</td>
<td></td>
<td></td>
<td>0.68</td>
<td>0.31–1.49</td>
</tr>
<tr>
<td>Region</td>
<td>Australia/W &amp; N Europe/US/Canada ($N = 1575$)</td>
<td></td>
<td></td>
<td>0.99</td>
<td>0.74–1.34</td>
</tr>
<tr>
<td></td>
<td>C &amp; S Europe/Israel/Russia ($N = 308$)</td>
<td></td>
<td></td>
<td>1.37</td>
<td>0.74–2.54</td>
</tr>
<tr>
<td></td>
<td>South America ($N = 59$)</td>
<td></td>
<td></td>
<td>1.44</td>
<td>0.39–5.37</td>
</tr>
<tr>
<td></td>
<td>Asia/New Zealand/South Africa ($N = 649$)</td>
<td></td>
<td></td>
<td>0.66</td>
<td>0.42–1.05</td>
</tr>
<tr>
<td>Race</td>
<td>Asian ($N = 613$)</td>
<td></td>
<td></td>
<td>0.70</td>
<td>0.43–1.15</td>
</tr>
<tr>
<td></td>
<td>Black ($N = 61$)</td>
<td></td>
<td></td>
<td>1.64</td>
<td>0.27–9.84</td>
</tr>
<tr>
<td></td>
<td>Other ($N = 17$)</td>
<td></td>
<td></td>
<td>1.67</td>
<td>0.25–11.16</td>
</tr>
<tr>
<td></td>
<td>White ($N = 1900$)</td>
<td></td>
<td></td>
<td>1.00</td>
<td>0.77–1.31</td>
</tr>
<tr>
<td>Menopausal status</td>
<td>Post ($N = 1250$)</td>
<td></td>
<td></td>
<td>1.16</td>
<td>0.83–1.62</td>
</tr>
<tr>
<td></td>
<td>Pre ($N = 1341$)</td>
<td></td>
<td></td>
<td>0.79</td>
<td>0.58–1.08</td>
</tr>
<tr>
<td>Tumor size, cm</td>
<td>0–&lt;2 ($N = 939$)</td>
<td></td>
<td></td>
<td>1.17</td>
<td>0.69–1.98</td>
</tr>
<tr>
<td></td>
<td>≥2–5 ($N = 1514$)</td>
<td></td>
<td></td>
<td>0.93</td>
<td>0.70–1.23</td>
</tr>
<tr>
<td></td>
<td>≥5 ($N = 132$)</td>
<td></td>
<td></td>
<td>0.84</td>
<td>0.45–1.58</td>
</tr>
<tr>
<td>No. of positive</td>
<td>0 ($N = 1640$)</td>
<td></td>
<td></td>
<td>0.79</td>
<td>0.56–1.13</td>
</tr>
<tr>
<td>lymph nodes</td>
<td>1–3 ($N = 638$)</td>
<td></td>
<td></td>
<td>1.01</td>
<td>0.65–1.56</td>
</tr>
<tr>
<td></td>
<td>≥4 ($N = 313$)</td>
<td></td>
<td></td>
<td>1.14</td>
<td>0.75–1.73</td>
</tr>
<tr>
<td>Adjuvant CT</td>
<td>Anthracycline ($N = 947$)</td>
<td></td>
<td></td>
<td>0.83</td>
<td>0.54–1.28</td>
</tr>
<tr>
<td></td>
<td>Anthracycline + taxane ($N = 1508$)</td>
<td></td>
<td></td>
<td>1.03</td>
<td>0.78–1.37</td>
</tr>
<tr>
<td></td>
<td>Taxane ($N = 136$)</td>
<td></td>
<td></td>
<td>0.63</td>
<td>0.24–1.66</td>
</tr>
<tr>
<td>Hormone receptor</td>
<td>ER and PgR negative ($N = 2453$)</td>
<td></td>
<td></td>
<td>0.93</td>
<td>0.73–1.17</td>
</tr>
<tr>
<td>status</td>
<td>ER and/or PgR low ($N = 138$)</td>
<td></td>
<td></td>
<td>1.42</td>
<td>0.46–4.34</td>
</tr>
<tr>
<td>Surgery</td>
<td>Breast-conserving surgery ($N = 1644$)</td>
<td></td>
<td></td>
<td>0.93</td>
<td>0.67–1.30</td>
</tr>
<tr>
<td></td>
<td>Mastectomy ($N = 947$)</td>
<td></td>
<td></td>
<td>0.95</td>
<td>0.69–1.31</td>
</tr>
</tbody>
</table>